Gujarat Themis Biosyn Limited (NSE:GUJTHEM)

Market Cap	37.53B +16.1%
Revenue (ttm)	1.59B +2.7%
Net Income	477.89M -9.2%
EPS	4.39 -9.1%
Shares Out	n/a
PE Ratio	78.54
Forward PE	n/a
Dividend	0.67 (0.21%)
Ex-Dividend Date	Sep 4, 2025

Volume	10,597
Average Volume	83,838
Open	335.60
Previous Close	340.75
Day's Range	331.75 - 339.80
52-Week Range	208.00 - 479.00
Beta	-0.37
RSI	50.35
Earnings Date	Feb 5, 2026

About Gujarat Themis Biosyn

Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease; Rifamycin-O for the treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy; and Lovastatin. The company was incorporated in 1981 and is based in Mumbai, India.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1981
• Employees: 221
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: GUJTHEM

Financial Performance

In fiscal year 2025, Gujarat Themis Biosyn's revenue was 1.51 billion, a decrease of -11.20% compared to the previous year's 1.70 billion. Earnings were 487.72 million, a decrease of -17.56%.